AC Immune SA (ACIU)
Nasdaq: ACIU · Pharmaceutical Preparations · 1015 Lausanne, CH · filing with the SEC since 2015
Who runs AC Immune SA
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Zuegel Martin
Interim CEO. First filing Apr 2026, latest Jun 15, 2026, 0 filings in all.
Officers reporting now
4
of 8 people with a filing in the last fifteen months
Directors reporting now
4
8 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Zuegel Martin | Interim CEO | Apr 2026 | Jun 15, 2026 | none |
| Pfeifer Andrea | Chief Executive Officer | Mar 2026 | May 18, 2026 | 2 · $100,000 |
| Donati Piergiorgio | Chief Operating Officer | Mar 2026 | Mar 20, 2026 | none |
| Roberts Christopher James | Chief Financial Officer | Mar 2026 | Mar 18, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Aguiar-Lucander Renee | director | Mar 2026 | Jun 15, 2026 | none |
| Buetler Monika | director | Mar 2026 | Jun 15, 2026 | none |
| June Carl Howard | director | Mar 2026 | Jun 15, 2026 | none |
| Twyman Roy Ervin | director | Mar 2026 | Jun 15, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.